Puma Biotech (PBYI) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Puma Biotechnology (PBYI) PT Raised to $37 at RBC Capital
March 1, 2019 6:51 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Puma Biotechnology (NASDAQ: PBYI) to $37.00 (from $29.00) while maintaining a Sector Perform rating following results.
MacKay called results "unexpectedly impressive" with +16% q/q growth versus a tepid +4% in Q3.
"Inventory confounds the... More
